Baricitinib (OOMC00059)

Catalog No: OOMC00059

Baricitinib, approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectivity inhibits Janus kinase 1 (IC₅₀=5.9 nM) and 2 (5.7 nM), over 3 (0.56 uM). It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems. Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome ("cytokine storm") induced by SARS-CoV-2 infection.

Product Info

• Product Format: Lyophilized White to off-white powder
• Additional Information: CAS: 1187594-09-7
  Molecular Formula: C₁₆H₁₇N₇O₂S
• Reconstitution and Storage: May be dissolved in DMSO (30 mg/ml) or DMF (50 mg/ml). Store desiccated as supplied at -20°C for up to 2 years. Store solutions at -20°C for up to 3 months.
• Purity: > 98% (HPLC); NMR (Conforms)

Target Info

• Alias Symbols: INCB 028050, LY3009104
• Molecular Weight: 371.4 g/mol